Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis

Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis

Background: Sacituzumab Govitecan (SG), a first-in-class anti-trophoblast cell surface antigen-2-directed antibody-drug conjugate (ADC), has shown clinically meaningful improvement in outcomes of patients with breast cancer (BC). However, it has also been accompanied by significant toxicity. Thus, w...

Full description

Saved in:
Bibliographic Details
Main Authors: Maria Inez Dacoregio, Isabella Michelon, Caio Ernesto do Rego Castro, Francisco Cezar Aquino de Moraes, Guilherme Rossato de Almeida, Lis Victória Ravani, Maysa Vilbert, Ricardo Lima Barros Costa
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Breast
Subjects:
Sacituzumab govitecan
Antibody-drug conjugates
TROP-2
IMMU-132
Breast cancer
Safety
Online Access:http://www.sciencedirect.com/science/article/pii/S096097762400184X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S096097762400184X

Similar Items